TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor

BACKGROUND: Immune checkpoint inhibitors (ICI) can achieve durable responses in a subset of patients with locally advanced or metastatic urothelial carcinoma (aUC). The use of tumor genomic profiling in clinical practice may help suggest biomarkers to identify patients most likely to benefit from IC...

Descripción completa

Detalles Bibliográficos
Autores principales: de Kouchkovsky, Ivan, Zhang, Li, Philip, Errol J, Wright, Francis, Kim, Daniel M, Natesan, Divya, Kwon, Daniel, Ho, Hansen, Ho, Son, Chan, Emily, Porten, Sima P, Wong, Anthony C, Desai, Arpita, Huang, Franklin W, Chou, Jonathan, Oh, David Y, Pruthi, Raj S, Fong, Lawrence, Small, Eric J, Friedlander, Terence W, Koshkin, Vadim S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118032/
https://www.ncbi.nlm.nih.gov/pubmed/33980590
http://dx.doi.org/10.1136/jitc-2020-002127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118032/
https://www.ncbi.nlm.nih.gov/pubmed/33980590
http://dx.doi.org/10.1136/jitc-2020-002127

Ejemplares similares